Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

In a more challenging regulatory environment for clinical trials, optimising trial designs early makes success more likely.

In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $100.00. The company’s shares closed yesterday at $67.67. According to ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Several SDGs are directly linked to taxation, especially those focused on poverty, hunger, health, education, equality, and ...

Learn what biotechnology is with simple explanations and fascinating examples! Discover hands-on science project ideas for ...

The EU has previously talked up agriculture as a key security concern. In the crisis preparedness plan presented last March, ...

Keith Shaw: Counterfeiting is no longer just about luxury goods or fake currency. It’s now infiltrating areas like ...

The 10-Year Health Plan paints a picture of a health service in 2035 that is prevention-focused, community-based and ...

If a gene is evolutionarily conserved, that shows it must be doing something important. Otherwise, nature would let it go.